Airborne viruses inside “germ factories”

| April 12, 2019

article image
Compared to bacteria and fungus, the airborne viral microbiome in built environments, is relatively understudied. Recently published research in Microbiome looks to address this imbalance by examining the virome of a daycare center over the course of a year and was inspired by the seasonal pattern of illnesses picked up by the author’s daughter in a similar daycare.

Spotlight

Psioxus Therapeutics

PsiOxus Therapeutics Ltd develops non-traditional therapeutics for serious diseases. We are an Oxford based development stage biotechnology company with world leading scientists and a highly experienced management team. Our approach is to combine different elements including small molecules, viruses, polymers and other macro-molecules to produce novel patent protected therapeutics. We deliberately target diseases that result in significant associated global morbidity and mortality, with a particular focus upon cancer

OTHER ARTICLES

Biotech: Finding The DNA For Success

Article | April 3, 2020

The integration of artificial intelligence within life sciences is making drug discovery and development more innovative, less labor intensive and more cost-effective, says Deloitte’s annual global outlook. According to Deloitte’s 2020 Global Life Sciences Outlook, the biotech sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of today’s wealth of data, the report overview says. As data-driven technologies provide biopharma and medtech organizations with treasure troves of information, and automation takes over some mundane tasks, new talent models are emerging based on purpose and meaning. The integration of artificial intelligence (AI) and machine learning approaches within life sciences is making drug discovery and development more innovative, time-effective and cost-effective, the Deloitte report states.

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Spotlight

Psioxus Therapeutics

PsiOxus Therapeutics Ltd develops non-traditional therapeutics for serious diseases. We are an Oxford based development stage biotechnology company with world leading scientists and a highly experienced management team. Our approach is to combine different elements including small molecules, viruses, polymers and other macro-molecules to produce novel patent protected therapeutics. We deliberately target diseases that result in significant associated global morbidity and mortality, with a particular focus upon cancer

Events